中国学者率先系统解析全球不同地区肝癌发病模式

2019-04-20 陈静 中新网

HBV感染依然是世界范围内导致肝癌的主要病因;在高收入的日本、韩国、新加坡、美国等国家,HCV是导致肝癌的主要病因;在澳洲以及西欧国家,酒精性肝癌则占比最高。

HBV感染依然是世界范围内导致肝癌的主要病因;在高收入的日本、韩国、新加坡、美国等国家,HCV是导致肝癌的主要病因;在澳洲以及西欧国家,酒精性肝癌则占比最高。

肝癌给全球造成了极为沉重的疾病负担,但不同地区肝癌发病模式差异较大。

复旦大学19日披露,该校人类表型组研究院陈兴栋青年研究员团队和公共卫生学院流行病教研室张铁军副教授团队合作研究率先发现,HBV(乙型肝炎病毒)感染依然是世界范围内导致肝癌的主要病因;在高收入的日本、韩国、新加坡、美国等国家,HCV(丙型肝炎由丙型肝炎病毒)是导致肝癌的主要病因;在澳洲以及西欧国家,酒精性肝癌则占比最高。

该研究还系统地解析了过去近30年全球的肝癌发病模式变化,阐明了不同地区肝癌防治的重点方向,具有重大的公共卫生意义。

中国学者在全球不同地区肝癌发病模式及主要病因方面取得的重要成果,以封面文章的形式发表于《肝脏病学杂志》 。杂志同期还配发了主编点评,并将该研究遴选为“Selection of Month”。

据了解,截至目前,多种因素已被证实是肝癌发病的危险因素,主要包括乙型肝炎病毒(HBV)、丙型肝炎病毒(HCV)、酒精和黄曲霉毒素等。在中国60%以上的肝癌是由HBV感染引起的,而在邻国日本的主要病因却是HCV感染。了解不同地区的肝癌发病模式,对于肝癌的精准预防以及治疗方案的选择十分重要。

据介绍,该研究系统分析了1990至2016年间,195个国家和地区的肝癌发病模式。HBV感染占比超过40%,在东亚和西非地区,这一比例超过50%。团队进一步对肝癌发病率变化趋势分析发现,不同地区、不同病因导致的肝癌发病率变化趋势呈明显的异质性。

研究人员发现,全球范围内,由HCV导致的肝癌发病率增速最快,而由酒精导致的肝癌处于平稳水平。在低中收入国家,肝癌呈现下降趋势,这主要是因为该地区有效控制了HBV的感染;在高收入的北美地区,HBV导致的肝癌却增速最快,这与当地HBV感染率的增长一致。在东欧地区,肝癌整体呈现上升趋势,其中由酒精导致的肝癌发病率增速最快,这与该地区居民既往高酒精摄入有关。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1799863, encodeId=afb41e99863aa, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Mon Mar 02 22:52:00 CST 2020, time=2020-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672919, encodeId=853016e2919e6, content=<a href='/topic/show?id=b79b910345c' target=_blank style='color:#2F92EE;'>#解析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91034, encryptionId=b79b910345c, topicName=解析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f42d26916490, createdName=hongbochen, createdTime=Mon Jun 10 10:52:00 CST 2019, time=2019-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364969, encodeId=36f13649690d, content=学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf771731979, createdName=派哥哥, createdTime=Sat Apr 20 14:41:35 CST 2019, time=2019-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040179, encodeId=c75610401e9dc, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Sat Apr 20 12:52:00 CST 2019, time=2019-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364953, encodeId=496036495396, content=哇, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2622354286, createdName=122b9cbbm13暂无昵称, createdTime=Sat Apr 20 12:23:26 CST 2019, time=2019-04-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1799863, encodeId=afb41e99863aa, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Mon Mar 02 22:52:00 CST 2020, time=2020-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672919, encodeId=853016e2919e6, content=<a href='/topic/show?id=b79b910345c' target=_blank style='color:#2F92EE;'>#解析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91034, encryptionId=b79b910345c, topicName=解析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f42d26916490, createdName=hongbochen, createdTime=Mon Jun 10 10:52:00 CST 2019, time=2019-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364969, encodeId=36f13649690d, content=学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf771731979, createdName=派哥哥, createdTime=Sat Apr 20 14:41:35 CST 2019, time=2019-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040179, encodeId=c75610401e9dc, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Sat Apr 20 12:52:00 CST 2019, time=2019-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364953, encodeId=496036495396, content=哇, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2622354286, createdName=122b9cbbm13暂无昵称, createdTime=Sat Apr 20 12:23:26 CST 2019, time=2019-04-20, status=1, ipAttribution=)]
    2019-06-10 hongbochen
  3. [GetPortalCommentsPageByObjectIdResponse(id=1799863, encodeId=afb41e99863aa, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Mon Mar 02 22:52:00 CST 2020, time=2020-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672919, encodeId=853016e2919e6, content=<a href='/topic/show?id=b79b910345c' target=_blank style='color:#2F92EE;'>#解析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91034, encryptionId=b79b910345c, topicName=解析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f42d26916490, createdName=hongbochen, createdTime=Mon Jun 10 10:52:00 CST 2019, time=2019-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364969, encodeId=36f13649690d, content=学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf771731979, createdName=派哥哥, createdTime=Sat Apr 20 14:41:35 CST 2019, time=2019-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040179, encodeId=c75610401e9dc, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Sat Apr 20 12:52:00 CST 2019, time=2019-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364953, encodeId=496036495396, content=哇, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2622354286, createdName=122b9cbbm13暂无昵称, createdTime=Sat Apr 20 12:23:26 CST 2019, time=2019-04-20, status=1, ipAttribution=)]
    2019-04-20 派哥哥

    学习了。

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1799863, encodeId=afb41e99863aa, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Mon Mar 02 22:52:00 CST 2020, time=2020-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672919, encodeId=853016e2919e6, content=<a href='/topic/show?id=b79b910345c' target=_blank style='color:#2F92EE;'>#解析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91034, encryptionId=b79b910345c, topicName=解析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f42d26916490, createdName=hongbochen, createdTime=Mon Jun 10 10:52:00 CST 2019, time=2019-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364969, encodeId=36f13649690d, content=学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf771731979, createdName=派哥哥, createdTime=Sat Apr 20 14:41:35 CST 2019, time=2019-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040179, encodeId=c75610401e9dc, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Sat Apr 20 12:52:00 CST 2019, time=2019-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364953, encodeId=496036495396, content=哇, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2622354286, createdName=122b9cbbm13暂无昵称, createdTime=Sat Apr 20 12:23:26 CST 2019, time=2019-04-20, status=1, ipAttribution=)]
    2019-04-20 留走人康

    肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1799863, encodeId=afb41e99863aa, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Mon Mar 02 22:52:00 CST 2020, time=2020-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672919, encodeId=853016e2919e6, content=<a href='/topic/show?id=b79b910345c' target=_blank style='color:#2F92EE;'>#解析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91034, encryptionId=b79b910345c, topicName=解析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f42d26916490, createdName=hongbochen, createdTime=Mon Jun 10 10:52:00 CST 2019, time=2019-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364969, encodeId=36f13649690d, content=学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf771731979, createdName=派哥哥, createdTime=Sat Apr 20 14:41:35 CST 2019, time=2019-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040179, encodeId=c75610401e9dc, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Sat Apr 20 12:52:00 CST 2019, time=2019-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364953, encodeId=496036495396, content=哇, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2622354286, createdName=122b9cbbm13暂无昵称, createdTime=Sat Apr 20 12:23:26 CST 2019, time=2019-04-20, status=1, ipAttribution=)]
    2019-04-20 122b9cbbm13暂无昵称

    0

相关资讯

新型“人工肌肉”问世,它是如何感知湿度的呢?

如果有件智能衣服,可以感知皮肤表面湿度,出汗时长袖变为短袖,汗干后又恢复如初,那将多么神奇。如今,这一设想已经成为可能。南开大学药物化学生物学国家重点实验室刘遵峰教授团队研发了一种绿色环保的纯蚕丝“人工肌肉”,可通过感知湿度实现自动伸缩。这种新型“人工肌肉”,可应用于柔软机器人研发和制造智能织物。日前,介绍该成果的论文发表于材料领域国际权威期刊《先进功能材料》上。

追忆301医院高长青院士,那个让无数人免去“开胸破肚”痛苦的人走了!

2019年的1月8号,这一天,离春节仅有不到一个月的时间,就在众人都沉浸在即将阖家团圆的喜悦中时,有个人永远地离开了我们。 他是高长青,提起他的名字可能许多人都觉得陌生,但是很多患者因为他的贡献而免去“开胸破肚”的痛苦。

我国学者主导国际共识在BMJ发表,轻型卒中应尽快给予氯吡格雷联合阿司匹林治疗

3月1日,《英国医学杂志》刊登以首都医科大学附属北京天坛医院王拥军教授为第一作者和通讯作者,由中国、美国、英国、中国香港和台湾等多个国家和地区脑血管病抗血小板领域专家联合署名的《轻型卒中与短暂性脑缺血发作(TIA)患者抗血小板治疗国际专家共识》。 《共识》指出,对于24小时内的轻型卒中与TIA患者,应尽快给予氯吡格雷联合阿司匹林双联抗血小板治疗,并持续21天。

柳叶刀:影响1200万人,中国颅脑损伤救治能力进步飞速

颅脑创伤是中国的一大公共卫生问题。《中国颅脑创伤》(Traumatic Brain Injury in China) 一文近日在《柳叶刀-神经病学》在线发表。中国颅脑创伤治疗现状如何?此领域的研究重点在哪里?未来该走向哪里?我们邀请文章通讯作者、上海交通大学医学院附属仁济医院首席专家江基尧教授做解读。

一篇中国学者的《新英格兰医学杂志》文章是怎样炼成的?

这是一篇讲述中国学者如何克服困难, 将原创研究推上世界知名学术舞台的文章。 2018年初,《新英格兰医学杂志》(NEJM)发表了复旦大学附属华山医院、国家老年疾病临床医学研究中心(华山)徐文东团队“健侧颈7移位术治疗中枢损伤后上肢痉挛瘫的临床试验”。 这项研究是一项手术新技术的临床试验,是完全中国原创的全新治疗策略,一经发表便在学术界和患者中引起了巨大反响。该文被NEJM编辑部评

Cell:老药开新花:阿司匹林有望治疗一类自身免疫疾病

环鸟腺苷酸合成酶(cGAS)作为DNA感受器,自被获得“科学突破奖”的华裔科学家陈志坚发现以来,即成为近年来生命科学领域科学家们热衷追寻的重要科学课题。